| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis
|
Leyssens, B.
|
|
|
21 |
2 |
p. 419-423
|
artikel
|
| 2 |
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
|
Viale, G.
|
|
|
21 |
2 |
p. 245-254
|
artikel
|
| 3 |
AIB1 is a predictive factor for tamoxifen response in premenopausal women
|
Alkner, S.
|
|
|
21 |
2 |
p. 238-244
|
artikel
|
| 4 |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
|
Tan, E.-H.
|
|
|
21 |
2 |
p. 217-222
|
artikel
|
| 5 |
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
|
Schmidt, M.
|
|
|
21 |
2 |
p. 275-282
|
artikel
|
| 6 |
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer
|
Michels, J.
|
|
|
21 |
2 |
p. 305-311
|
artikel
|
| 7 |
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
|
du Bois, A.
|
|
|
21 |
2 |
p. 370-375
|
artikel
|
| 8 |
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors
|
Sharma, S.
|
|
|
21 |
2 |
p. 297-304
|
artikel
|
| 9 |
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer
|
Mol, L.
|
|
|
21 |
2 |
p. 415-418
|
artikel
|
| 10 |
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)
|
Bramwell, V.H.C.
|
|
|
21 |
2 |
p. 283-290
|
artikel
|
| 11 |
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
|
Kataoka, Y.
|
|
|
21 |
2 |
p. 255-262
|
artikel
|
| 12 |
Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer
|
Donnem, T.
|
|
|
21 |
2 |
p. 223-231
|
artikel
|
| 13 |
Communication skills training in oncology: a position paper based on a consensus meeting among European experts in 2009
|
Stiefel, F.
|
|
|
21 |
2 |
p. 204-207
|
artikel
|
| 14 |
Concomitant medications in cancer patients: should we be more active in their management?
|
Lord, S.
|
|
|
21 |
2 |
p. 430
|
artikel
|
| 15 |
Daidzein induces MCF-7 breast cancer cell apoptosis via the mitochondrial pathway
|
Jin, S.
|
|
|
21 |
2 |
p. 263-268
|
artikel
|
| 16 |
Darwin, medicine and cancer
|
Purushotham, A.D.
|
|
|
21 |
2 |
p. 199-203
|
artikel
|
| 17 |
Editorial board
|
|
|
|
21 |
2 |
p. ii-iii
|
artikel
|
| 18 |
Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials
|
Regan, M.M.
|
|
|
21 |
2 |
p. 312-318
|
artikel
|
| 19 |
European Society for Medical Oncology (ESMO) Program for the Integration of Oncology and Palliative Care: a 5-year review of the Designated Centers’ incentive program
|
Cherny, N.
|
|
|
21 |
2 |
p. 362-369
|
artikel
|
| 20 |
Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006–2010
|
Pulte, D.
|
|
|
21 |
2 |
p. 335-341
|
artikel
|
| 21 |
Health care-related predictors of husbands’ preparedness for the death of a wife to cancer—a population-based follow-up
|
Hauksdóttir, A.
|
|
|
21 |
2 |
p. 354-361
|
artikel
|
| 22 |
Identifying optimal adjuvant treatment for individual patients: young age is still an issue?
|
Crivellari, D.
|
|
|
21 |
2 |
p. 430-431
|
artikel
|
| 23 |
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
|
Varettoni, M.
|
|
|
21 |
2 |
p. 325-330
|
artikel
|
| 24 |
in this issue
|
|
|
|
21 |
2 |
p. 191
|
artikel
|
| 25 |
Irinotecan and mismatch repair deficiency
|
Power, D.G.
|
|
|
21 |
2 |
p. 432-433
|
artikel
|
| 26 |
Malignant peritoneal mesothelioma: a multicenter study on 81 cases
|
Manzini, V. de Pangher
|
|
|
21 |
2 |
p. 348-353
|
artikel
|
| 27 |
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
|
Perez, E.A.
|
|
|
21 |
2 |
p. 269-274
|
artikel
|
| 28 |
Now's the time to find biomarkers on purpose
|
Auman, J.T.
|
|
|
21 |
2 |
p. 193-194
|
artikel
|
| 29 |
Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib
|
Blay, J.-Y.
|
|
|
21 |
2 |
p. 208-215
|
artikel
|
| 30 |
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
|
Wakelee, H.A.
|
|
|
21 |
2 |
p. 376-381
|
artikel
|
| 31 |
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
|
Wirth, L.J.
|
|
|
21 |
2 |
p. 342-347
|
artikel
|
| 32 |
Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors
|
Lim, W.T.
|
|
|
21 |
2 |
p. 382-388
|
artikel
|
| 33 |
Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
|
Mussi, C.
|
|
|
21 |
2 |
p. 403-408
|
artikel
|
| 34 |
Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent
|
Anaya, D.A.
|
|
|
21 |
2 |
p. 397-402
|
artikel
|
| 35 |
Potential role of everolimus in inducing cholestasis
|
Pantano, F.
|
|
|
21 |
2 |
p. 433
|
artikel
|
| 36 |
Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice
|
Tassinari, D.
|
|
|
21 |
2 |
p. 428-429
|
artikel
|
| 37 |
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
|
Sonpavde, G.
|
|
|
21 |
2 |
p. 319-324
|
artikel
|
| 38 |
Table of Contents
|
|
|
|
21 |
2 |
p. iv-vi
|
artikel
|
| 39 |
Taxanes for breast cancer during pregnancy: a systematic review
|
Mir, O.
|
|
|
21 |
2 |
p. 425-426
|
artikel
|
| 40 |
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy
|
Gill, S.
|
|
|
21 |
2 |
p. 331-334
|
artikel
|
| 41 |
The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control
|
Proctor, S.J.
|
|
|
21 |
2 |
p. 426-428
|
artikel
|
| 42 |
The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit
|
Wheatley-Price, P.
|
|
|
21 |
2 |
p. 232-237
|
artikel
|
| 43 |
Treatment and survival in breast cancer in the Eastern Region of England
|
Wishart, G.C.
|
|
|
21 |
2 |
p. 291-296
|
artikel
|
| 44 |
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)
|
Colomer, R.
|
|
|
21 |
2 |
p. 195-198
|
artikel
|
| 45 |
Trends in cancer mortality in the elderly in Japan, 1970–2007
|
Yang, L.
|
|
|
21 |
2 |
p. 389-396
|
artikel
|
| 46 |
VEGFR TKI ‘resistance’ or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma
|
Ravaud, A.
|
|
|
21 |
2 |
p. 431-432
|
artikel
|
| 47 |
Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study
|
Quaglino, P.
|
|
|
21 |
2 |
p. 409-414
|
artikel
|
Tijdschrift beschrijving